Profound Medical Corp. (PROF)

Market Cap	184.93M +2.9%
Revenue (ttm)	16.10M +50.7%
Net Income	-42.57M
EPS	-1.41
Shares Out	36.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	189,640
Open	5.14
Previous Close	5.16
Day's Range	5.02 - 5.21
52-Week Range	3.76 - 8.95
Beta	0.39
Analysts	Strong Buy
Price Target	12.00 (+137.15%)
Earnings Date	Mar 5, 2026

About PROF

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 162
• Stock Exchange: NASDAQ
• Ticker Symbol: PROF
• Website: https://www.profoundmedical.com

Financial Performance

In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.

Analyst Summary

According to one analyst, the rating for PROF stock is "Strong Buy" and the 12-month stock price target is $12.0.

Price Target

$12.0

(137.15% upside)

Analyst Consensus: Strong Buy